Scarica l'app Stockscreener
27.71
0.40%
-0.11
Dopo l'orario di chiusura:
27.82
0.11
+0.40%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HIMS Giù?
Forum
Previsione
Precedente Chiudi:
$27.82
Aprire:
$27.73
Volume 24 ore:
6.60M
Relative Volume:
0.41
Capitalizzazione di mercato:
$6.47B
Reddito:
$2.35B
Utile/perdita netta:
$128.37M
Rapporto P/E:
53.07
EPS:
0.5221
Flusso di cassa netto:
$57.42M
1 W Prestazione:
-3.92%
1M Prestazione:
-13.84%
6M Prestazione:
+68.45%
1 anno Prestazione:
-42.40%
Intervallo 1D:
$27.38
$27.95
Intervallo di 1 settimana:
$27.38
$29.87
Portata 52W:
$13.74
$65.30
Hims Hers Health Inc Stock (HIMS) Company Profile
Nome
Hims Hers Health Inc
Settore
Telefono
415-851-0195
Indirizzo
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
27.71 | 7.43B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
18.45 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.36 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.60 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
75.81 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
487.61 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-24 | Iniziato | JP Morgan | Overweight |
| 2026-03-10 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2026-03-10 | Aggiornamento | Citigroup | Sell → Neutral |
| 2026-03-09 | Aggiornamento | Needham | Hold → Buy |
| 2026-02-24 | Downgrade | BTIG Research | Buy → Neutral |
| 2026-01-12 | Iniziato | Evercore ISI | In-line |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-10-21 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Downgrade | Needham | Buy → Hold |
| 2025-06-04 | Reiterato | Needham | Buy |
| 2025-04-29 | Downgrade | TD Cowen | Buy → Hold |
| 2025-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Downgrade | Citigroup | Neutral → Sell |
| 2025-01-07 | Iniziato | BTIG Research | Buy |
| 2024-12-17 | Iniziato | Morgan Stanley | Overweight |
| 2024-11-14 | Downgrade | BofA Securities | Buy → Underperform |
| 2024-08-22 | Iniziato | Needham | Buy |
| 2024-08-09 | Downgrade | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Downgrade | Citigroup | Buy → Neutral |
| 2024-04-16 | Downgrade | Jefferies | Buy → Hold |
| 2024-04-10 | Iniziato | Canaccord Genuity | Buy |
| 2024-02-28 | Aggiornamento | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Iniziato | Leerink Partners | Market Perform |
| 2023-12-07 | Iniziato | Imperial Capital | In-line |
| 2023-07-28 | Iniziato | TD Cowen | Outperform |
| 2023-04-11 | Iniziato | Robert W. Baird | Neutral |
| 2023-02-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-11-08 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Iniziato | Truist | Hold |
| 2022-07-15 | Iniziato | SVB Leerink | Underperform |
| 2022-04-14 | Iniziato | Guggenheim | Buy |
| 2022-04-01 | Ripresa | Credit Suisse | Outperform |
| 2022-03-10 | Iniziato | Deutsche Bank | Hold |
| 2021-12-02 | Iniziato | Jefferies | Hold |
| 2021-11-11 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Iniziato | BofA Securities | Neutral |
| 2021-05-20 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Iniziato | Truist | Hold |
| 2021-03-09 | Iniziato | Credit Suisse | Neutral |
| 2021-03-02 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-02-17 | Iniziato | Citigroup | Neutral |
| 2021-02-12 | Iniziato | Piper Sandler | Neutral |
| 2021-02-08 | Iniziato | Tigress Financial | Buy |
Mostra tutto
Hims Hers Health Inc Borsa (HIMS) Ultime notizie
HIMS Looks 20.9% Undervalued on GF Value™ Despite Credit Dispute Penalties - GuruFocus
Hims & Hers Health Inc (HIMS) Shares Surge 6.0% -- What GF Score of 82 Tells Investors - GuruFocus
Hims & Hers Health facing penalties from Visa for credit card disputesreport - Seeking Alpha
Hims & Hers faces Visa penalties over dispute surgeBloomberg By Investing.com - Investing.com Canada
HIMS Stock Has Quadrupled In 5 Years: How Hims Turned A $3 Stock Into A Telehealth Giant - Stocktwits
Hims’ Weight-Loss Plans Draw Penalties Over Credit Card Disputes - Bloomberg.com
Hims & Hers Health (HIMS) Stock Falls 14.73% After FTC Lawsuit; Law Firm Launches Securities Investigation - kalkine.ca
Bragar Eagel & Squire, P.C. is Investigating Hims & Hers - GlobeNewswire
HIMS Maintained by Barclays -- Price Target Lowered to $35 - GuruFocus
Barclays Issues Pessimistic Forecast for Hims & Hers Health (NYSE:HIMS) Stock Price - MarketBeat
HIMS Stock More Than Doubled in 6 Months: What's Driving the Rally? - TradingView
Hims & Hers Health Inc (HIMS) Chief Legal Officer Soleil Boughto - GuruFocus
Hims & Hers Health (HIMS) & Novo Nordisk A/S (NVO): Two Weight-Loss Pill Players Just Got Punished for Growing Fast - Yahoo Finance
Hims & Hers Health (NYSE:HIMS) CFO Oluyemi Okupe Sells 4,938 Shares - MarketBeat
Hims & Hers Health (NYSE:HIMS) Insider Soleil Boughton Sells 25,111 Shares of Stock - MarketBeat
Hims & Hers Health (NYSE:HIMS) Insider Deborah Autor Sells 16,773 Shares - MarketBeat
Hims & Hers (NYSE: HIMS) policy chief sells shares under 10b5-1 plan - Stock Titan
Hims & Hers Health Options Spot-On: On August 20th, 143.18K Contracts Were Traded, With 928.8K Open Interest - Moomoo
Hims & Hers Health Stock Trades Below The Market On Revenue And Above It On Cash - Trefis
Hims & Hers faces federal lawsuit and price tar... - Pluang
Barclays cuts Hims and Hers stock price target on margin pressure - Investing.com Canada
Hims & Hers Stock Jumped 14% Yesterday. The CEO’s CNBC Interview Is Why. - TIKR.com
Hims & Hers Health (NYSE: HIMS) CEO Disposes Of 78,859 Shares In Routine Tax Withholding Event - foreignpolicyjournal.com
FTC, California and Utah Sue Telehealth Company Hims & Hers for Deceptive and Unlawful Privacy Practices - Hunton Andrews Kurth LLP
Hims & Hers CEO Defends Data Practices, Projects Sharp Drop in Weight-Loss Drug Prices - finance.biggo.com
Hims & Hers Health (NYSE:HIMS) Stock Price Up 10.8%What's Next? - MarketBeat
Hims & Hers CFO Sells $3.2 Million in Stock Amid Leadership Transition - finance.biggo.com
Hims & Hers Rejects Privacy Allegations While Promising Expanded Patient Access - Benzinga
Hims & Hers Health sees 17x international reven... - Pluang
Wellness Briefing: Hims & Hers plots rapid expansion into peptide therapies like BPC-157, plus news - glossy.co
Hims & Hers: Buying The Margin Dip (NYSE:HIMS) - Seeking Alpha
Berger Montague PC Investigates Hims & Hers Health, Inc.'s Board of Directors for Breach of Fiduciary Duty (HIMS) - marketscreener.com
Hims & Hers' Chief Accounting Officer Is Leaving. Here's What Her Latest Insider Filing Shows - The Motley Fool
An Insider at Hims & Hers Just Filed. Here's What It Says About Buying the Dip - The Motley Fool
What Long-Term Investors Should Know About This Hims Insider Filing - The Motley Fool
A Hims & Hers Insider Disposed of Stock as the Company Pushes Into Testosterone and Peptides. Here's What to Know - The Motley Fool
Hims & Hers' Policy Chief Just Filed an Insider Transaction. Here's What It Means. - The Motley Fool
An Insider at Hims & Hers Disposed of Over $3 Million in Stock. Here's What Long-Term Investors Should Know - The Motley Fool
The CTO of Hims & Hers Just Gave Up Nearly $2.7 Million in Stock. Here's What It Actually Means - The Motley Fool
Hims & Hers' CEO Just Disposed of 78,859 Shares. Here's What Long-Term Investors Should Know. - The Motley Fool
An Insider at Hims & Hers Just Filed. Here's What It Says About Buying the Dip - The Motley Fool
Companies with huge datasets can save up to 80% in AI costs by using open-weight models: Hims CEO - Business Insider
Hims & Hers Health Boosts Revenue Target, Swings to Second-Quarter Loss - wsj.com
Hims & Hers faces FTC lawsuit over privacy brea... - Pluang
Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm - PR Newswire
Is Hims & Hers Health Inc (HIMS) a Bargain After 4.3% Drop? GF V - GuruFocus
Why Is Hims & Hers Health (HIMS) Facing A New Privacy Lawsuit? - Yahoo Finance
Oluyemi Okupe Sells 55,383 Shares of Hims & Hers Health (NYSE:HIMS) Stock - MarketBeat
Insider Selling: Hims & Hers Health (NYSE:HIMS) CFO Sells $261,831.32 in Stock - MarketBeat
Hims & Hers Health (NYSE: HIMS) Stock Plunges 14% Following - GlobeNewswire
Hims & Hers CEO Andrew Dudum Says AI Health Coach Could Be Just 12 Months Away, Believes It Could Increase Medication Adherence - Stocktwits
Hims Hers Health Inc Azioni (HIMS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Hims Hers Health Inc Azioni (HIMS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Okupe Oluyemi | Chief Financial Officer |
Aug 19 '26 |
Option Exercise |
5.01 |
4,938 |
24,739 |
269,055 |
| Okupe Oluyemi | Chief Financial Officer |
Aug 19 '26 |
Sale |
29.99 |
4,938 |
148,111 |
264,117 |
| Boughton Soleil | Chief Legal Officer |
Aug 19 '26 |
Sale |
27.55 |
25,111 |
691,808 |
313,964 |
1.66%
0.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):